Romatoid artriti olan kadın hastada hidroksiklorokin kullanımına bağlı gelişen akut psikotik bozukluk: Olgu sunumu

Klorokin ve ondan sentez edilen hidroksiklorokin (HCQ) sıtmanın akut ve idame tedavisinde son yüzyılda yaygın olarak kullanılmaktadır. HCQ'nin antiinflamatuvar, antilipidemik ve antitrombotik etkileri vardır ve son yıllarda romatoid artrit tedavisinde önemli hale gelmiştir. Yazında antimalaryal kullanımına bağlı psikoz birkaç vaka sunumunda bildirilmiş fakat romatoid artritte HCQ kullanımına bağlı bir olguya rastlanmamıştır. Bu olgu sunumunda psikoz öyküsü olmayan 73 yaşında RA'i olan yaşlı kadın hastada HCQ kullanımına bağlı gelişen psikoz vakasını sunduk. HCQ otoimmün hastalıkların tedavisinde yaygın olarak reçete edilmeye başlanmıştır. Klinisyenlerin nadir ancak işlevselliği bozan bir yan etki olan psikoz konusunda uyanık olmaları gerekmektedir

Hydroxychloraquine-Induced Acute Psychotic Disorder in A Female Patient with Rheumatoid Arthritis: A Case Report

Chloroquine and its derivative hydroxychloroquine (HCQ) have been used for acute and prophilactic treatment of malaria for most of the last century. HCQ has anti-inflammatory, antilipidemic and antithrombotic effects and in recent years has become an important drug for treating rheumatoid arthritis (RA). In the literature, antimalarial-induced psychosis has been reported in a small number of cases; however, we did not find any case related with HCQ-induced psychosis in rheumatoid arthritis. We want to report a 73-year-old female RA patient without a previous history of psychosis who developed psychosis after use of HCQ. HCQ is being increasingly prescribed in autoimmune diseases. Clinicians need to be aware of psychosis as a rare but debilitating side effect

Kaynakça

1. Blyth C, Lane C. Hydroxychloroquine retinopathy: is screening necessary? BMJ 1998; 316:716-717. [CrossRef]

2. Weniger H. Review of side effects and toxicity of chloroquine. Bulletin World Health Organization 1979; 906:1-26.

3. Sahoo S, Kumar M, Sinha VK. Chloroquine-induced recurrent psychosis. Am J Ther 2007; 14: 406-407. [CrossRef]

4. Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1988; 26:303-313. [CrossRef]

5. Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Saf 1995; 12:370- 383. [CrossRef]

6. Mohan D, Mohandas E, Rajat R. Chloroquine psychosis: a chemical psychosis? J Natl Med Assoc 1981; 73:1073-1076.

7. Alisky JM, Chertkova EL, Iczkowski KA. Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis. Med Hypotheses 2006; 67:1090- 1094. [CrossRef]

8. Schneider C, Adamcova M, Jick SS, Schlagenhauf P, Miller MK, Rhein HG, Meier CR. Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders. Travel Med Infect Dis 2013; 11:71-80. [CrossRef]

9. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Clinical Version (SCID-I/CV, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute, 1997.

10. Corapcioglu A, Aydemir O, Yildiz M, Esen A, Koroglu E. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinical Version. Hekimler Yayin Birligi, Ankara, 1999. (Turkish)

11. Guy W. CGI: Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept of Health, Education, and Welfare publication (ADM) 76-338. Rockville; National Institute of Mental Health 1976:218-222.

12. Sadock BJ, Sadock VA. Kaplan&Sadock’s Comprehensive Textbook of Psychiatry. Aydin H, Bozkurt A (Translation Editors), Eight Edition, Günes Kitabevi, Ankara; 2007:1423-1424.

13. Ochsendorf FR, Runne U. Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs. Hautarzt 1991; 42:140-146.

14. Telgt DS, van der Ven AJ, Schimmer B, Droogleever-Fortuyn HA, Sauerwein RW. Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection. Ann Pharmacother 2005; 39:551-554. [CrossRef]

15. Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 2004; 27:203-213. [CrossRef]

16. Bhatia MS, Malik SC. Psychiatric complications of chloroquine. Indian J Psychiatry 1994; 36:85-87.

17. Das P, Rai A, Chopra A, Philbrick K. Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology. Psychosomatics 2014; 55:409-413. [CrossRef]

18. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41:67-76. [CrossRef]

Kaynak Göster